ArticleJournal, genetic engineering & biotechnology2025
Bioinformatics and experimental validation of MAPK pathway activation in diabetic kidney disease induced by glucose variability.
Article in Journal, genetic engineering & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploring the potential targets and mechanisms of artemisinin in the treatment of diabetic kidney disease using network pharmacology and molecular docking.Functional & integrative genomics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis article aims to evaluate the role of factors associated with oxidative stress induction in fluctuating hyperglycemia-induced diabetic kidney disease (DKD) and to elucidate the molecular mechanisms underlying the pathogenesis of DKD.
methodsWe downloaded the gene expression datasets GSE30528 and GSE30529, which are associated with diabetic kidney disease (DKD), from the Gene Expression Omnibus (GEO) database. We identified differentially expressed genes (DEGs) and selected the top four proteins from protein-protein interaction (PPI) networks using STRING and Cytoscape software. Concurrently, we conducted diabetic animal experiments to verify that these proteins contribute to the onset and progression of DKD through oxidative stress. Finally, we confirmed the correlation and roles of these genes in the animal model.
resultThe modulation of the MAPK cascade involves ITGB2 and TYROBP. The results showed that the areas under the ROC curve (AUC) for TYROBP were 0.889 and 0.966, respectively, while for ITGB2, they were 0.906 and 0.974. All other indicators had an AUC of 1.0; these indicators represent differentially expressed genes identified through data analysis. The activities of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px), as well as the levels of malondialdehyde (MDA), were measured in diabetic rats (P < 0.05). Apoptotic responses and c-Jun N-terminal kinase (JNK) activation were evident in the rat fluctuation group. Further research has demonstrated that oxidative stress regulates the MAPK pathway at both cellular and molecular levels. Gene and protein expression, particularly in the context of diabetic nephropathy, are influenced by multiple factors.
conclusionCollectively, fluctuating hyperglycemia directly and indirectly regulates MAPK-JNK signaling via ITGB2, TYROBP, and oxidative stress, ultimately influencing the onset and progression of diabetic nephropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.